Xanomeline

From WikiMD's WELLNESSPEDIA

Xanomeline


Xanomeline is a muscarinic acetylcholine receptor agonist that has been studied for its potential therapeutic uses, particularly in the treatment of Alzheimer's disease and schizophrenia. It was first synthesized in the late 20th century and has been the subject of numerous clinical trials.

History[edit]

Xanomeline was first synthesized in the 1990s by scientists at Lilly Research Laboratories. The compound was developed as a potential treatment for Alzheimer's disease and schizophrenia, due to its ability to stimulate muscarinic acetylcholine receptors in the brain.

Pharmacology[edit]

Xanomeline is a muscarinic acetylcholine receptor agonist. It has a high affinity for the M1 and M4 subtypes of this receptor, which are primarily found in the brain. By stimulating these receptors, xanomeline can increase the activity of the cholinergic system, which is often impaired in individuals with Alzheimer's disease and schizophrenia.

Clinical Trials[edit]

Several clinical trials have been conducted to evaluate the efficacy of xanomeline in treating Alzheimer's disease and schizophrenia. In a phase II trial conducted by Lilly Research Laboratories, xanomeline was found to improve cognitive function and reduce psychotic symptoms in patients with Alzheimer's disease. However, the drug also caused significant side effects, including nausea and increased salivation, which led to the discontinuation of the trial.

Current Status[edit]

As of 2021, xanomeline is not approved for use in any country. However, research into its potential therapeutic uses continues. A prodrug of xanomeline, known as KarXT, is currently being developed by Karuna Therapeutics for the treatment of schizophrenia and other psychiatric disorders.

See Also[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!




Alzheimer's disease topics
Basics
Treatment
Research
Society and culture
Related conditions
This Alzheimer's disease related article is a stub.



Schizophrenia
Causes and risk factors
Diagnosis and management
Symptoms and prognosis
Types
History


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Xanomeline&oldid=5368490"